MBC JOURNAL

Monday, June 16, 2025

Juiced and Jeopardized: How Hormone Abuse Fuels Male Breast Cancer and Broader Malignancies

Written by: Lennard M. Goetze, Ed.D / Nancy Chu, PhD

Introduction: Breaking the Silence on Male Hormone Use and Cancer Link

Male breast cancer (MBC) represents a small yet growing part of the global cancer burden—accounting for approximately 1% of the 1.67 million breast cancer cases diagnosed annually worldwide¹. That translates to roughly 20,000 new cases per year, with a lifetime risk of about 1 in 800 men¹. This rarity, combined with a cultural stigma, often obscures warning signs until advanced stages. Added to that danger is a booming subculture of “juicing”—the use of anabolic androgenic steroids (AAS), testosterone, and growth hormones to sculpt larger muscles and youthful physiques. Despite gym culture glorifying “pump,” mounting evidence indicates that these potent hormones may elevate the risk not just of MBC, but other cancers including prostate, liver, and skin malignancies. This article explores how hijacking the endocrine system through excess hormone intake elevates cancer risk in men—and calls for greater awareness before the next workout goes too far.

Understanding Male Breast Cancer: Beyond the X Chromosome

Male breast cancer often involves hormone-sensitive pathways similar to female breast cancer. About 80–95% of MBC tumors express androgen receptors (AR), while most also have estrogen receptors (ERα)—opening the door to hormonal carcinogenesis². Genetic risk factors play a role: BRCA2 mutations appear in approximately 12% of MBC cases, compared to 5% in women, while BRCA1 mutations are rare (~1%)¹. Other conditions such as Klinefelter syndrome, liver cirrhosis, and testicular dysfunction increase MBC risk by disrupting normal hormonal balance—especially when estrogen levels become disproportionately high¹.

"Juicing" and Hormonal Carcinogenesis: Busting the Risks

“Juicing” refers to the non-medical use of high-dose AAS, testosterone, and other hormones to build muscle. Often ingested at 10–100× therapeutic doses, taken cyclically or stacked with multiple compounds, these protocols radically alter the body’s hormone milieu³.

AAS and Male Breast Cancer
Aromatization—where testosterone converts into estrogen—rises directly with high-dose AAS use. Drugs like nandrolone and stanozolol have been shown in vitro to stimulate estrogen-sensitive breast cancer cell lines, increasing ER–dependent mitogenic signals and cyclin D-mediated proliferation⁴. While large-scale observational data are limited, associations between anabolic steroid use, gynecomastia (male breast growth), and potential breast tumorigenesis are well documented⁵. The off-label use of breast cancer medications like tamoxifen and Arimidex by bodybuilders to mitigate these effects further illustrates the perceived risk⁶.
Juicing and Broader Cancer Risk
Some cohort studies—such as one involving over 1,000 Danish fitness-center users followed for over a decade—found no statistically significant increase in overall cancer incidence (IRR 1.05; 95% CI: 0.55–1.81), and no breast or prostate cancer cases among steroid users. However, the same study reported a markedly higher post-diagnosis mortality rate in the androgen-using group (HR 3.07; 95% CI: 1.35–7.00)⁷.

Beyond breast and prostate, high testosterone has been linked to increased melanoma risk in men, with a large UK Biobank study suggesting a direct biological association⁸. Additionally, the International Agency for Research on Cancer classifies AAS as “probably carcinogenic to humans” (Group 2A)⁹.
Mechanisms: Hormones, Receptors, and DNA Damage

Estrogen receptor activation: Elevated estrogen during AAS use can stimulate ERα pathways, increasing cell cycle proliferation (e.g., cyclin D1 overexpression) and reducing apoptosis⁴.
Androgen receptor overdrive: AR is frequently overexpressed in MBC and other cancers. Excessive androgen binding may alter transcription networks that support tumor growth and evasion².
IGF‑1/growth hormone axis: Often elevated by exogenous hormones, this pathway promotes mitosis and cell survival—and high IGF‑1 levels are implicated in colorectal, breast, and prostate cancers⁴.
Immune suppression: Supra-physiological steroids and corticosteroids suppress immune function, potentially hampering tumor surveillance and enabling early cancer progression¹⁰.

"Hormones, Hubris, and Hidden Risks: The Oncologic Cost of Anabolic Steroid Abuse" An Endocrinologist’s Perspective on Male Breast Cancer and Hormonal Carcinogenesis

By: Dr. Angela Mazza

Under thorough analysis of anabolic-androgenic steroids (AAS) and their potential cancer risks, these synthetic derivatives of testosterone commonly used to enhance muscle mass and athletic performance are not without RED FLAGS. While their body-building effects are well documented, increasing evidence points to significant cancer-related risks associated with their misuse, particularly with prolonged use and supraphysiologic dosing. Among these, the development of hormone-sensitive malignancies, including male breast cancer (MBC), is of particular concern.

As an endocrinologist, I have seen the untoward effects of these drugs. AAS disrupt the hypothalamic-pituitary-gonadal (HPG) axis, leading to a cascade of hormonal imbalances that do not always resolve after these drugs are stopped. Exogenous testosterone and its derivatives undergo aromatization to estradiol, resulting in elevated estrogen levels in men. This hyperestrogenic state, compounded by suppressed endogenous testosterone and reduced gonadotropin secretion, creates a milieu that mimics estrogen dominance—a recognized risk factor for the development of gynecomastia and potentially malignant transformation in breast tissue. Case reports and epidemiological data, although limited due to the rarity of MBC, have documented instances of breast carcinoma in men with a history of prolonged AAS use, particularly in those who developed gynecomastia years prior to diagnosis.

In addition to hormone-sensitive tissues, AAS have been implicated in hepatic malignancies, including hepatocellular carcinoma and hepatic adenomas, largely due to the hepatic metabolism of 17α-alkylated oral steroids. AAS have also demonstrated genotoxic and epigenetic effects, such as DNA strand breaks, oxidative stress, and aberrant methylation patterns, which may contribute to tumorigenesis. Immunosuppression linked to chronic AAS exposure further reduces immune surveillance, facilitating the progression of transformed cells.

Despite these concerns, definitive large-scale prospective studies linking AAS use directly to cancer incidence remain scarce. However, the biological plausibility, supported by mechanistic studies and clinical observations, warrants caution. Given the rising prevalence of AAS use in non-athletic populations and bodybuilders, often in unregulated or illicit contexts, awareness and screening for hormone-related cancers in users should be prioritized.

While causality cannot yet be established with high certainty, the evidence supports a credible link between chronic anabolic steroid use and increased cancer risk, particularly in hormone-sensitive tissues such as the male breast. Medical professionals should maintain vigilance and counsel patients on the potential oncogenic consequences of AAS abuse.

About Dr. Angela Mazza

Dr. Mazza is a triple board-certified endocrinologist, integrative medicine specialist, and founder of Metabolic Center for Wellness in Oviedo, Florida. With a career dedicated to hormone optimization, thyroid health, and functional longevity, Dr. Mazza blends conventional endocrine care with personalized, root-cause medicine. She is nationally recognized for her leadership in advancing patient-centered approaches to hormonal disorders, and she frequently speaks on the links between endocrine disruption and chronic disease—including cancer. Dr. Mazza is a vocal advocate for early detection, particularly in overlooked populations such as men at risk for hormone-sensitive cancers like male breast cancer. Her work empowers both patients and practitioners to understand the broader impact of environmental and pharmaceutical hormone exposures on long-term health. She continues to collaborate with clinical researchers and advocacy organizations to elevate awareness, improve screening protocols, and promote integrative strategies for cancer prevention and endocrine resilience.

* Check out additional stories like this from www.DrAngelaMazza.com

Statistical Landscape & Real‑World Cases

Cancer Type	Incidence/Comments
Male Breast Cancer (MBC)	~20,000 new global cases/year (~1 in 800 men)¹
Androgen User Cohort	1,189 users vs 59,450 controls; IRR 1.05 overall, HR 3.07 post-diagnosis⁷
Melanoma (High Testosterone)	Linked to elevated risk in men⁸
AAS Carcinogenicity	Group 2A: probably carcinogenic to humans⁹

Case reports of liver adenomas, hepatic carcinoma, and rare male breast tumors continue to appear in medical literature. Although anecdotal, they highlight the real dangers of extreme hormone misuse.

Interventions and Moving Forward

Stricter regulation: While the Designer Anabolic Steroid Control Act of 2014 expanded controlled substances lists, illicit gym-grade AAS remain easily accessible via black markets¹.
Medical screening: Physicians should inquire about AAS use in men showing gynecomastia or early MBC signs; consider endocrine paneling and breast imaging.
Harm reduction in gyms: Coaches and trainers can help reduce risks by discouraging off-label hormone use and encouraging natural muscle-building strategies.
Public outreach: Awareness campaigns need to include male audiences about hormone risks—not just for heart health, but for cancer surveillance too.

Conclusion: When “Muscle” Meets Malignancy

The subculture of “juicing” may promise dramatic gains, but those gains come at a potentially deadly cost. Male breast cancer—once rare—is now rising in incidence worldwide, and although MBC has long been overlooked, it may be a sentinel warning of broader hormone-induced malignancies. The data may not fully capture the risk yet, but biological mechanisms are clear: excessive hormones fuel estrogenic and androgenic signaling, abet malignant growth, and impair the immune system’s ability to suppress aberrant cells. Even when cancer appears, outcomes post-diagnosis may be significantly worse in those with a history of AAS use.

Our cultural fascination with rapid transformation through endocrine manipulation demands urgent reevaluation. Until robust trials clarify the full risks, anecdotal signals—gynecomastia, hormone dependence, and deadly cancer outcomes—must not be ignored. Especially for men stepping onto the juicing path, awareness isn’t just power—it may be life-saving. Let’s pump iron, not hormones; build strength, not regrets.

Footnotes

(1) Wikipedia contributors. (2025, June). Male breast cancer. Wikipedia. https://en.wikipedia.org/wiki/Male_breast_cancer (2) Shen, Y., et al. (2018). Characterizing steroid hormone receptor chromatin binding in male breast cancer. Nature Communications. https://doi.org/10.1038/s41467-018-04502-2 (3) Wikipedia contributors. (2025, June). Anabolic steroid. Wikipedia. https://en.wikipedia.org/wiki/Anabolic_steroid (4) Penna, A., et al. (2017). Anabolic androgenic steroids and carcinogenicity: Focus on breast cancer mechanisms. Journal of Experimental Oncology. (5) Breastlink. (2025). Male Breast Cancer and Gynecomastia. https://www.breastlink.com/blog/male-breast-cancer-gynecomastia (6) Med News Today. (2024). Bodybuilders using tamoxifen and Arimidex to control gynecomastia. (7) Sørensen, H., et al. (2024). Excessive androgen exposure and cancer risk: A cohort study. Andrology Journal. (8) Cancer Research UK. (2021, March 31). New link between high testosterone in men and increased risk of melanoma. https://www.cancerresearchuk.org (9) International Agency for Research on Cancer (IARC). (2020). IARC Monographs on the Identification of Carcinogenic Hazards to Humans: Anabolic Steroids. (10) Antoni, M. H., Lutgendorf, S. K., Cole, S. W., et al. (2006). The influence of bio-behavioural factors on tumour biology: Pathways and mechanisms. Nature Reviews Cancer, 6(3), 240–248.

“DROP THE BIAS” is the campaign and battle cry of the Male Breast Cancer Global Alliance—a bold call to end the harmful misconception that breast cancer is a “women-only” disease. This bias in medicine, media, and society creates dangerous blind spots in care, leaving men misdiagnosed, undertreated, or ignored. It limits access to screening, support, and survivor recognition. But bias also lives within—men often avoid seeking help out of fear, stigma, or shame. “DROP THE BIAS” confronts this cultural and clinical oversight head-on, urging the world to recognize that men get breast cancer too. The campaign is not just about awareness—it’s about action. By challenging outdated assumptions, educating providers, empowering survivors, and opening dialogue, the Alliance aims to rewrite the narrative and save lives. “DROP THE BIAS” is a mission, a movement, and a message to all: equity in cancer care starts with truth.

The information provided in this article is a compiled report from public websites whose links are listed in the FOOTNOTES OR REFERENCE section and the statements and quotes included are from actual interviews by those whose names are stated who provided express consent to the publishing of this material. This article is not meant to be used to diagnose, treat or advise others about what actions they should take with regard to any medical condition. No one should undertake or discontinue any treatment as a result of what they read on our blogs. The publisher(s), editors or sponsors are providing a strictly educational or editorial service and are not responsible for the diagnosis or treatment of any specific health needs. Writers and publishers are not liable for any damages or negative consequences from any treatment, action, application or preparation to any person(s) reading the information in this article or its thread. Readers with medical needs should obtain appropriate professional medical supervision. References are provided for any informational purposes only and do not constitute endorsement of any websites or other sources.

What does it mean to be part of a MEDICAL ADVISORY BOARD?

By: Lennard M. Goetze, Ed.D

Joining a Medical Advisory Board (MAB) for a nonprofit organization like the Male Breast Cancer Global Alliance (MBCGA) is far more than an honorary position—it is a meaningful commitment to cancer advocacy, clinical excellence, and community impact. It represents the joining of skilled hands and brilliant minds to uplift a shared mission: to end the silence, address the bias, and advance the science around male breast cancer.

The role of an MAB member is multifaceted. These dedicated clinicians, researchers, and health experts become a vital extension of the organization’s purpose, bringing real-time expertise and evidence-based insight to support every facet of the Alliance’s work. From authoring educational content to contributing to public policy conversations, these advisors help ensure the MBCGA remains a trusted and medically credible resource for patients, caregivers, and advocates around the world.

At its core, the advisory board fuels knowledge. Members may collaborate to publish white papers, clinical commentaries, and research summaries. They review and validate health information distributed to the public, ensuring accuracy, clarity, and sensitivity. Their expertise helps to translate complex science into patient-centered resources that foster understanding and action.

Beyond publishing, advisory board members play a key role in collaboration. They serve as sounding boards for new programs and campaigns, providing clinical oversight to public health initiatives. Whether it's reviewing screening recommendations for high-risk men or participating in early detection campaigns, their guidance is instrumental in shaping the Alliance’s efforts and effectiveness.

Importantly, these professionals lend their voices in public forums. Advisory board members often serve as guest speakers for national seminars, media events, and webinars, offering powerful insights that bridge research and reality. By sharing clinical experiences and the latest updates in diagnosis, treatment, and survivorship, they amplify awareness and encourage informed decisions.

But being on a medical advisory board also comes with a deeper human responsibility. MBCGA is not just an advocacy group—it’s a growing family of survivors, caregivers, researchers, and clinicians bound together by compassion and a commitment to equity. Advisory board members provide reassurance, clarity, and hope to a community that too often feels overlooked in the breast cancer landscape. They serve as educators, but also as advocates—using their credentials to shine a light on the disparities and stigmas that keep men from getting the care they deserve.

Together, the MAB and MBCGA leadership work in synergy to build a living resource—a place where patients and their families can find expert guidance, clinical direction, and compassionate support. Every contribution—whether it's reviewing a medical blog, joining a research panel, or advising on screening protocols—ripples outward to affect lives directly.

In cancer advocacy, the clinical voice is vital. It elevates the mission from awareness to action. To join a medical advisory board like that of the Male Breast Cancer Global Alliance is to step into a legacy of leadership. It is to stand for evidence-based change, to guide a movement with integrity, and to make a lasting difference in how the world sees—and treats—male breast cancer.

For clinicians and researchers who believe in the power of purpose, this is more than a board—it’s a call to serve.

Disclaimer & Copyright Notice: The materials provided on this web-based article are copyrighted and the intellectual property of the publishers/producers (The MBC Global Alliance). It is provided publicly strictly for informational purposes within non-commercial use and not for purposes of resale, distribution, public display or performance. Unless otherwise indicated on this web based page, sharing, re-posting, re-publishing of this work is strictly prohibited without due permission from the publishers. Also, certain content may be licensed from third-parties. The licenses for some of this Content may contain additional terms. When such Content licenses contain additional terms, we will make these terms available to you on those pages (which his incorporated herein by reference).The publishers/producers of this site and its contents such as videos, graphics, text, and other materials published are not intended to be a substitute for professional medical advice, diagnosis, or treatment. For any questions you may have regarding a medical condition, please always seek the advice of your physician or a qualified health provider. Do not postpone or disregard any professional medical advice over something you may have seen or read on this website. If you think you may have a medical emergency, call your doctor or 9-1-1 immediately. This website does not support, endorse or recommend any specific products, tests, physicians, procedures, treatment opinions or other information that may be mentioned on this site. Referencing any content or information seen or published in this website or shared by other visitors of this website is solely at your own risk. The publishers/producers of this Internet web site reserves the right, at its sole discretion, to modify, disable access to, or discontinue, temporarily or permanently, all or any part of this Internet web site or any information contained thereon without liability or notice to you.

The information provided in this article is a compiled report from public websites whose links are listed in the FOOTNOTES OR REFERENCE section and the statements and quotes included are from actual interviews by those whose names are stated who provided express consent to the publishing of this material. This article is not meant to be used to diagnose, treat or advise others about what actions they should take with regard to any medical condition. No one should undertake or discontinue any treatment as a result of what they read on our blogs. The publisher(s), editors or sponsors are providing a strictly educational or editorial service and are not responsible for the diagnosis or treatment of any specific health needs. Writers and publishers are not liable for any damages or negative consequences from any treatment, action, application or preparation to any person(s) reading the information in this article or its thread. Readers with medical needs should obtain appropriate professional medical supervision. References are provided for any informational purposes only and do not constitute endorsement of any websites or other sources.

Survivor Stories: Spotlight on DERRICK CAMERON

In 2009 I noticed a lump under on my chest while I was in the shower one day. This occurred during flag football season, so I figured it was a deep tissue bruise. After a couple of months when it didn’t go away, I decided to go to the doctor because it seemed to be getting larger. After the physician requested an ultrasound, then a biopsy, I was called for a return visit for my test results. I remember when the doctor told me I had cancer and by heart sank. I became terrified. How could a man get breast cancer? I am only 32 years old – does this happen to young people often? My first question was, “How long do I have to live?” I had to get my thoughts together and figure out what the entire process would be. There were a lot of decisions made quickly, including finding an oncologist I would be comfortable with.

After initial consultations, I began my journey with my treatments in early 2010. I started with a double mastectomy to reduce the risk of the cancer returning on the opposite side of my chest. I followed my surgery with five months of chemotherapy treatments. Each treatment would last between 5 to 8 hours per visit. It was a very challenging time but I had great support from family and friends. Chemotherapy is extremely hard; there are so many things that occur in a person, and every person reacts differently to the treatment. Different side effects may occur in people who take chemotherapy, and the same side effect can have different reactions for patients. The first drug I took made me feel like I had ants crawling under the skin. The second drug affected my taste; as soon as the nurse began the injection, I tasting what seemed like metal, a very weird sensation. As if the effects from the first two drugs weren’t enough, the third—nicknamed “red devil”—was the hard one. Imagine a seven-inch long, one-inch diameter syringe full of a drug thick enough to be syrup.

The effects of dealing with cancer are great in magnitude. Mentally, I went through so many thoughts including questions about my family’s genetic code. Was this passed along in my family, and would I pass it along to my offspring? What will people say or think about me? How will people treat me? My short-term memory was affected as well.

The battle educated me about cancer in so many areas. I learned about the chemicals used to kill the cancer cells. I learned more about my strength and perseverance. I already had established my faith and grew up in the church. But cancer made me pray harder and trust more than I ever had, resulting in increased, everlasting faith. I quickly appreciated life and relationships more.

I learned more about relationships during my time of going through treatments then I may have learned in a decade. The entire journey was so powerful that I decided to write a book called “The Strength of a Man” so that it may help other men prepare for a winnable battle. I have also become a big advocate for men to go to the doctor – I sure have changed my perspective positively about annual checkups.

All the real men will take responsibility in taking care of their bodies and monitoring their health. I may not have been able to prevent getting breast cancer but having breast cancer did not make me any less of a man. In fact, breast cancer made me a better man.

IF YOU ARE A MALE BREAST CANCER SURVIVOR, WE WANT TO HEAR FROM YOU! Contact us at support@mbcga.org or visit our website: www.mbcglobalalliance.org

Knowing Your Genes Could Save Your Children: The Truth About Male Breast Cancer and Genetic Risk

Yeah, you read that right. Breast cancer doesn't care if you have pecs instead of breasts. It's time to kill the myth: male breast cancer is real, dangerous, and often overlooked. But here’s what most men don’t know: this isn't just about you—it's about your kids. Your genes carry the story, and if you don’t know your predisposition, you might be passing down a deadly risk to your sons and daughters.

GENETIC PREDISPOSITION TESTING FOR POTENTIAL HEREDITARY DISEASES: Genetic mutation can be inherited. When a specific cancer type is prevalent in one side of the family, the cancer is recognized as a FAMILIAL cancer. Most of them are caused by genetic mutation in a gene related to cancer susceptibility. In addition, a term called "family cancer syndrome" (or "hereditary cancer syndrome") is a rare disorder in which family members have an above-average chance of developing a certain type or types of cancer. Family cancer syndromes are caused by inherited genetic variants in certain cancer-related genes. It is reported that up to 10% of all cancer cases may be caused by inherited genetic mutation or changes. These are called CANCER PREDISPOSITION genes. Individuals who carry a mutant allele of these genes have an increased susceptibility to cancer. It is now widely identified that an accumulation of genetic or epigenetic alterations affect the conversion of normal cells to cancer cells. (See complete report) This isn't just awareness. This is a wake-up call.

For more information about the MALE BREAST CANCER GLOBAL ALLIANCE PREDISPOSITION TESTING PROGRAM, contact us at: www.mbcglobalalliance.org or contact our hotline at: 516.522-0777

Breaking the Silence: How Dr. Robert Bard’s Imaging Innovations Are Revolutionizing Rare Cancer Detection Special Report – Diagnostic Frontlines | June 2025

In a healthcare landscape that often overlooks rare and aggressive cancers, one name continues to challenge the status quo with precision, passion, and purpose: Dr. Robert L. Bard, a globally recognized leader in cancer imaging. With a relentless mission to advance early detection and redefine standards of care, Dr. Bard is pioneering new technologies that are transforming how we fight cancer—especially the forms too often missed.

"Every cancer missed is a life put at risk," says Dr. Bard, whose practice in New York City has become a diagnostic epicenter for patients seeking clarity, second opinions, and advanced screening when conventional tools fall short. His work is especially focused on rare and understudied cancers, such as male breast cancer, sarcomas, and pediatric anomalies—cases where early detection is crucial, but frequently delayed or dismissed.

At the heart of his approach is a suite of non-invasive, real-time imaging modalities that push beyond the limitations of traditional scans. These include:

· 3D Doppler Ultrasound for blood flow analysis and angiogenesis mapping;

· Elastography, a revolutionary tool to measure tissue stiffness and distinguish between benign and malignant lesions;

· Thermographic Imaging, which visualizes abnormal heat patterns from inflammatory or vascular activity;

· AI-integrated second opinion systems, offering patients and physicians critical review data for better-informed decisions.

Dr. Bard’s practice also champions active surveillance programs—helping patients monitor suspicious lesions over time without unnecessary procedures. “We’re not just finding cancers earlier,” he says. “We’re managing them smarter.”

He is currently spearheading multiple clinical research initiatives, working in collaboration with advocacy organizations and imaging device developers to validate emerging technologies for rare cancer diagnostics. His goal? To reshape outdated protocols and offer clinicians globally-accessible tools that support early, actionable findings.

“Imaging is our frontline weapon in saving lives,” Dr. Bard asserts. “My personal challenge is to bring this power to cancers that have been neglected for far too long.”

With every scan, every case, and every innovation, Dr. Robert Bard is proving that science, when driven by compassion and courage, can rewrite the future of cancer care.

Produced by: Bobbi Kline MD / Roberta Kline MD #human design #longevity #wellness

Sunday, June 15, 2025

2025 State Bill Proposal for Ultrasound Use for Male Breast Cancer

June 2025 – New York, NY — In a bold step toward medical equity, Dr. Lennard Goetze, national advocate for early detection and communications director of the Male Breast Cancer Global Alliance recently launched a groundbreaking proposal for New York State Senators (and those from other states) that seek to improve cancer screening and prevention protocols. These lawmakers are also anticipated to see the value of advanced ultrasound as the preferred diagnostic tool for male breast cancer. Backed by the Male Breast Cancer Global Alliance (MBCGA) and renowned diagnostic expert Dr. Robert Bard, the bill underscores the urgent need to revise outdated imaging protocols that have long failed male patients.

“This is not just a medical update—it’s a public health imperative,” says Dr. Goetze. “For too long, men with breast cancer have been an afterthought in our screening policies. It's time we change the narrative and the tools we use to save lives.”

WHY ULTRASOUND?
While mammography remains the standard screening modality for women, its use in men has repeatedly shown technical shortcomings. Male anatomy lacks the dense breast tissue and contours that mammograms were designed to image. Instead, high-resolution ultrasound offers a non-invasive, anatomically accurate, and highly sensitive alternative for detecting subdermal tumors in male breast tissue.

According to Dr. Robert Bard, a leading cancer imaging radiologist, “Ultrasound enables us to visualize abnormalities in the male breast with superior clarity. The male chest wall and flatter profile make mammograms less effective and, in many cases, inconclusive. This bill recognizes science—and common sense.”

LEGISLATIVE CALL TO ACTION
This proposed bill calls on legislators on a state-by-state level —particularly those who have championed breast screening laws for women—to now extend that same life-saving commitment to male patients facing breast cancer risk. The legislation seeks to:

• Mandate insurance coverage for ultrasound as a reimbursable screening tool for men, especially those at high risk;

• Designate ultrasound as the primary imaging modality for men with flat chest anatomy, where mammography is less effective;

• Promote early detection initiatives tailored specifically to male breast cancer risk factors;

• Support alignment with NCCN guidelines, which recommend regular clinical breast exams—and, in some cases, imaging—for men with BRCA1 or BRCA2 mutations.

By closing this diagnostic and policy gap, the bill affirms a broader commitment to equitable cancer care and timely detection for all.

With growing survivor testimony and increasing public support, the legislation is part of a national momentum to address gender bias in cancer detection.

Cheri Ambrose, co-founder of the MBCGA, adds: “This bill is a turning point for advocacy. It tells men everywhere that their lives matter. That their health matters. And that science is finally catching up.”

MALE BREAST CANCER: A SILENT CRISIS
Male breast cancer accounts for approximately 1% of all breast cancer cases, yet men are often diagnosed at more advanced stages. This delay stems from two key barriers: lack of awareness and inadequate screening tools. Many men are unaware they are at risk—particularly those with a family history or BRCA1/BRCA2 genetic mutations—and insurance coverage for imaging is inconsistent at best.

Dr. Goetze’s proposal speaks directly to this gap. “When we delay diagnosis, we limit outcomes. If we want to change survivorship rates, we must enable early, accurate detection for men—starting with insurance-covered ultrasound screening.”

A BROADER VISION FOR MEN’S HEALTH
The bill aims to raise public awareness about the clinical advantages of ultrasound use, while promoting the message that breast cancer is not just a woman’s disease. Through collaboration with advocacy groups, clinicians, and cancer survivors, Dr. Goetze and his allies seek to dismantle stigma, encourage open dialogue, and improve access to preventive care for all. Dr. Goetze’s leadership stems from his deep commitment to health equity. As a clinical researcher, an educator and a voice for underserved patient populations, his proposal champions both clinical accuracy and human compassion.

JOIN THE MOVEMENT
This initiative is currently in pursuit of State Senate committee review. Dr. Goetze, the MBCGA, and allied medical leaders urge the public to get involved:

• Contact your legislators to express support;

• Use the hashtag #UltrasoundForMen to spread awareness;

• Share survivor stories and advocate for male-inclusive screening policy.

For more information or to support this campaign, visit www.MBCGlobalAlliance.org or contact the Office of Dr. Lennard Goetze @ 516-522-0777

A Unified Front Against Male Breast Cancer: Advocates ULTRASOUND Diagnostics, and a Lifesaving Bill

As the conversation around men’s health gains overdue momentum, a powerful coalition of medical pioneers and advocacy leaders has emerged to drive transformative change—starting with a new proposal to designate ultrasound as the primary screening modality for male breast cancer.

At the center of this movement is Cheri Ambrose, founder of the Male Breast Cancer Global Alliance (MBCGA), who has spent over a decade giving voice to the often-silent epidemic of male breast cancer. Her mission has always been clear: equality in care, visibility in diagnosis, and respect for the men and families impacted by this disease.

“Men deserve to be seen, heard, and protected,” says Ambrose. “This bill is not just a diagnostic update—it’s a declaration that male breast cancer matters. It’s a chance to save lives with the right tools, at the right time.”

This advocacy now intersects with science through the work of Dr. Robert L. Bard, internationally recognized radiologist and imaging expert, who was recently appointed Chair of Clinical Diagnostics for the MBCGA. A pioneer in using high-resolution, Doppler-based ultrasound imaging to detect cancers in men, Dr. Bard brings decades of expertise in early detection to the legislative table. “Male anatomy demands a different approach,” explains Dr. Bard. “Ultrasound is not just an option—it is the most precise and practical solution for male breast screening. I’ve seen it save lives.”

His leadership in developing non-invasive diagnostic protocols has reshaped standards in imaging across multiple cancer types. With Dr. Bard’s appointment, the MBCGA’s mission gains a powerful clinical dimension, ensuring that real science drives real change.

Together, Ambrose and Bard represent the perfect alliance of advocacy and innovation. Their unified voice, amplified through this bill, signals a new era in cancer care—where male patients are no longer overlooked, and where the right diagnosis can happen early enough to make all the difference.

Thursday, June 12, 2025

June is Men’s Health Month: Get Awareness about MEN'S BREAST CANCER!

June marks Men’s Health Month, a time to challenge outdated beliefs and confront the lesser-known truth: men can develop breast cancer too. Although rare, male breast cancer is real — and often underdiagnosed. Many men are unaware they’re at risk, leading to delays in detection and treatment. Common signs include lumps, skin dimpling, nipple changes, or discharge. Recognizing these symptoms early can make all the difference.

At the Male Breast Cancer Global Alliance (MBCGA), we’re committed to bringing male breast cancer out of the shadows. We support men facing this disease, amplify survivor voices, and connect patients with cutting-edge care and global research. Our mission is to eliminate stigma, promote early diagnosis, and push for equity in treatment.

Men at higher risk — including those with BRCA mutations, family history, hormonal imbalances, or environmental toxin exposure — should speak with their doctors and consider regular screenings. Firefighters, veterans, and industrial workers are particularly vulnerable.

Let’s end the myth that breast cancer is only a women’s issue. It’s time to speak up, get checked, and protect our men. This Men’s Health Month, we urge every man to take charge of his health. Awareness leads to action. Action leads to survival.

Get informed. Get checked. Get involved. Visit www.mbcglobalalliance.org to learn more.

PHOTO INDEX

Click to enlarge

From our award-winning poster (above), meet nine of our dads who sent us pix from their latest Father’s Day celebration. Check out their stories in our website. These courageous men (among so many others) are more than survivors—they are warriors, role models, and living proof that early detection saves lives.

(1) Ron Whittecar (2) Marc Ruiz (3) Paul Heying Jr (4) Troy Flint (5) Keith Parker (6) Reuben Board (7) Michael Landesberg (8) Jeff Landin (9) Jason Esquerra

Each photo captures a story of strength: dads surrounded by family, celebrating life, resilience, and the power of support. From backyards to brunch tables, these moments reflect joy reclaimed after a life-changing diagnosis of male breast cancer. Through treatment, recovery, and advocacy, these fathers now inspire others to take charge of their health and raise awareness that men get breast cancer too. We honor them and all DADS this Father’s Day and thank them for standing proudly with the Male Breast Cancer Global Alliance.

A WORD FROM THE DOC

Father’s Day and June’s Men’s Health Month are more than annual reminders to honor the men in our lives—they’re critical moments to spark life-saving conversations. As a cancer diagnostic specialist, I’ve seen firsthand how Male Breast Cancer (MBC) continues to fly under the radar. It’s rare, but it’s very real. And too often, it’s caught late because men don’t believe it can happen to them.

MBC is not just a footnote in men’s health—it’s a serious and rising concern, especially among those with family histories, BRCA mutations, or occupational toxic exposures. That’s why being proactive is everything. If you're a man—or someone who loves one—take the first step today. Get Checked! Do a clinical breast exam. Talk to your doctor. And if you have a family history of breast or ovarian cancer, ask about genetic predisposition testing. Identifying a risk early can lead to regular monitoring and even prevention.

Men’s health is not just about muscles or heart disease—it’s about awareness, action, and knowing your body. Let’s rewrite the script on MBC, together.

—

Robert L. Bard, MD

Chair of Clinical Diagnostics / www.MBCScan.com

Advisory Board Member, Male Breast Cancer Global Alliance

Saturday, June 7, 2025

"Male Breast Cancer: The Silent Surge Men Can’t Afford to Ignore"

A Physician’s Mission to Expose, Detect, and Defend Against an Overlooked Crisis

By Robert L. Bard, MD - Diagnostic Imaging Specialist | Cancer Research Advocate

Introduction: Breaking the Silence on a Misunderstood Threat - The mention of “breast cancer” typically conjures an image of a woman—an understandable reaction shaped by decades of awareness campaigns and pink-ribbon advocacy. But breast cancer is not exclusive to women. It happens in men too, and more often than many realize. The most dangerous part? Most male patients—and their doctors—don’t see it coming.

As a cancer imaging specialist, I’ve spent decades on the frontlines of early detection. What alarms me isn’t just the number of male breast cancer (MBC) cases I’ve encountered, but how easily they are missed, misdiagnosed, or outright ignored. That’s not due to biology—it’s due to bias and a critical lack of data. As I often say, “It’s only rare because of the lack of data.” That absence of awareness is costing lives, and it’s time we change that.

What Is Male Breast Cancer—and Why Aren’t We Talking About It? - Male breast cancer occurs when malignant cells form in the tissues of the male breast—yes, men do have breast tissue. While it accounts for less than 1% of all breast cancer diagnoses, its mortality rate is disproportionately high because most cases are discovered late. Symptoms often go unreported, overlooked, or dismissed until the disease has progressed.

Historical Blind Spots and Gender Bias - For decades, male breast cancer has fallen through the cracks of public health research and screening guidelines. With studies historically focused on women, male-specific risks and diagnostic patterns remain poorly understood. This has led to a deep-rooted and dangerous misconception: that breast cancer is solely a “woman’s disease.” But cancer is biologically indifferent—it targets tissue, not gender identity.

Global Perspective and Growing Numbers - International data reveals a slow but steady rise in male breast cancer cases. However, due to inconsistent reporting and the lack of routine male screening, the true global burden is underestimated. These silent statistics underscore the urgent need for universal awareness and inclusive diagnostic strategies—ones that are not restricted by borders, or by bias.

A New Era of Imaging: Changing the Narrative with Technology - Advanced imaging is one of the most powerful tools in reversing the tide of male breast cancer. As a pioneer in diagnostic ultrasound, I’ve seen firsthand how high-resolution, non-invasive scans can detect abnormalities long before they become life-threatening.

Technologies like thermal imaging, B-mode ultrasound, Doppler scanning, and elastography have all enhanced our ability to visualize tumors and vascular patterns in male breast tissue. These tools are not only faster and safer than traditional biopsies—they offer real-time insights that enable early, decisive action.

By adopting proactive imaging protocols for men—especially those with family history, hormone imbalances, or unexplained chest masses—we can shift the paradigm from reactive diagnosis to proactive health preservation.

What Makes MBC Different in Men? - Unlike women, men are not typically screened for breast cancer. With less breast tissue, tumors are often closer to the chest wall, increasing the risk of deeper invasion. Compounding this is the fact that men tend to delay seeking medical attention—often due to embarrassment, misperceptions, or a lack of awareness.

Hormonal differences also play a crucial role. While estrogen is a known factor in breast cancer development, we’re witnessing a disturbing rise in testosterone-related complications. In collaboration with endocrinologist Dr. Angela Mazza, I’ve explored mounting evidence linking hormone modulation—particularly synthetic testosterone used in bodybuilding—to elevated cancer risk.

When men self-medicate with anabolic steroids, they disrupt their endocrine balance. This may trigger estrogenic pathways or inflammatory processes that promote breast tissue proliferation and tumor formation. Moreover, thyroid dysfunction—often unexamined in this context—can exacerbate these hormonal imbalances and should be a standard part of any risk assessment.

The Mission of the Male Breast Cancer Global Alliance - The Male Breast Cancer Global Alliance (MBCGA) exists to rewrite the narrative around MBC. As one of its active supporters, I see our work as far more than advocacy—it’s a movement. MBCGA champions data collection, patient support, and clinical innovation through global partnerships and multidisciplinary collaboration.

Together, we are establishing new standards: hormonal screening for at-risk men, comprehensive imaging protocols, and public education initiatives tailored to male populations. This alliance is helping fill the massive void left by decades of gendered oversight in cancer care. As I’ve often told my colleagues and patients alike, “It’s not just about detecting disease—it’s about protecting lives through education, partnership, and persistence.”

Need for Improved Programming - The lack of research, data, and early screening programs for male breast cancer is not just an academic oversight—it’s a public health emergency. My diagnostic practice now includes initiatives that specifically target this gap. I’ve established national and international programs to raise awareness, expand imaging access, and build registries that give researchers the tools they need. Every patient missed is a life potentially lost. We must build data. We must build awareness. We must build systems that include everyone at risk.

Conclusion: Let’s Redefine the Norms—Before More Lives Are Lost: We are living in an era of unparalleled medical tools—precision diagnostics, advanced imaging, integrative endocrinology. There is no longer an excuse for ignorance. Male breast cancer isn’t a statistical outlier—it’s a dangerously underestimated reality that has lived too long in the shadows.

If we are to save lives, we must update our clinical radar, erase the gender bias in our protocols, and embrace technological innovation as our first line of defense. Breast cancer advocacy must evolve from being color-coded and gendered to truly inclusive.

Because cancer doesn’t discriminate—and neither should we.

# # #

---------------------------------------------------------------------------------------------------------------------------

SPOTLIGHT: THE BATTLE IS ON

The MBCGA honors David Engle. It's been a unique and rewarding journey to meet and document the countless stories of those afflicted with Male Breast Cancer. In our website, we bring you the many unsung advocates that offer their compelling experience with the hopes of saving others.

"I was 70 years old when I was diagnosed. My double mastectomy was deemed a success with clear surgical margins and minimal lymphatic involvement. I did not require radiation therapy or chemotherapy subsequent to my surgery. I will be taking tamoxifen for up to 5 years as a precautionary measure against recurrence. So far, I’ve managed the side effects of this drug without too much difficulty." - Check out his complete story @ https://mbcglobalalliance.org/stories/david-engle/

ALSO, JOIN OUR ONLINE MBC GLOBAL ALLIANCE GROUP ON LINKEDIN @: https://www.linkedin.com/groups/8877080/

NEW BOOST FOR 2025 GLOBAL ADVOCACY DRIVE: LEN GOETZE IS NEW MBCGA PARTNERSHIP DIRECTOR

FOR IMMEDIATE RELEASE

Lennard Goetze Appointed National Cancer Community Outreach Director

May 5, 2025 – The Male Breast Cancer Global Alliance (MBCGA) proudly announces the appointment of Lennard Goetze as its new National Cancer Community Outreach Director. A veteran in executive fundraising, strategic partnerships, and public advocacy, Mr. Goetze brings more than 30 years of distinguished leadership to this growing mission.

Lennard's impressive career includes pivotal roles in nationwide cancer initiatives, including the Leukemia & Lymphoma Society, the 9/11 CancerScan Project, Firefighters Against Cancer Exposures, LI2DAY, the Are You Dense? Foundation and the New York Cancer Resource Alliance. His passion for advocacy is matched by a track record of building cross-sector alliances and mobilizing influential networks.

Leading MBCGA’s Vision for 2025 and Beyond: “Lennard’s work has always inspired me,” says Cheri Ambrose, President and CEO of MBCGA. “Our 2025 leadership team is a dynamic force of professionals and visionaries, and having Lennard on board marks a bold step forward. His ability to unite thought leaders and champion cause-driven action will bring fresh momentum to our mission.”

A Legacy of Networking and Action: Renowned for his expertise in alliance-building, Mr. Goetze has dedicated much of his career to connecting professionals across industries. His early outreach efforts in 2001 focused on supporting firefighters affected by post-9/11 toxic exposures—an experience that helped cement his lifelong commitment to cancer awareness and prevention. His mastery of modern communication platforms, including LinkedIn, has furthered his reputation as a sought-after connector and advocate in the cancer care community.

Fueling MBCGA’s 2025 Expansion- In his new role, Lennard is tasked with spearheading MBCGA’s next phase of growth, including strategic development of educational programs, publishing initiatives, research partnerships, and outreach alliances.

He joins forces with internationally acclaimed imaging expert Dr. Robert L. Bard, who recently unveiled a 10-year retrospective of his groundbreaking work in rare cancer diagnostics using advanced ultrasound technologies (TheCancerDetective.org). Lennard Goetze’s appointment also strengthens collaboration with MBCGA’s Cancer Advisory Committee, which includes some of the top distinguished professionals in cancer care.

The complete list of cancer advisors is available at www.mbcglobalalliance.org.

A Global Call to Action - As MBCGA enters a transformative era, its mission expands beyond borders. With Lennard leading outreach initiatives and a coalition of respected medical leaders driving research and education, the organization is launching a series of international collaborations to elevate male breast cancer awareness on a global stage. Central to this effort is a renewed focus on leveraging social media platforms and digital networks to break the silence, dispel the stigma, and engage the public with facts, faces, and survivor stories. MBCGA’s 2025 campaign underscores a clear message: male breast cancer is real, it is urgent, and together—with visibility and voices—we will bring change.